Fox Business - The Power to Prosper
Search Site

Synthes Holding AG

J&J Earnings Beat the Street

Johnson & Johnson (NYSE:JNJ) more than doubled its second-quarter earnings, with higher revenue and fewer charges boosting the health-care and consumer products giant.The company, which beat Wall Street expectations, also raised its full-year earnings outlook to $5.40 to $5.47 a share, up from $5.35 to $5.45.Shares were up 60 cents at $91.00 in pre-market trading. As of Monday's close, the stock is up 31.7% over the last 12 months.J&J reported a $3.83 billion profit, well above the $1.41 billion profit in the year-ago period. On a per-share basis, earnings were $1.33 versus 50 cents. Excluding one-time items, adjusted earnings climbed to $1.48 a share from $1.30 a share.Revenue jumped 8.5% to $17.88 billion.Analysts were looking for per-share earnings of $1.39 and revenue of $17.71 billion.Like other drug makers, J&J has set out to launch new drugs to offset the loss of certain patents and subsequent introduction of generic versions. It has launched 11 new drug products since 2009, and...

Read More

  1. J&J 1st-Quarter Profit Off 11% on Litigation Expenses, Acquisition-Related Items

    Johnson & Johnson's (JNJ) first-quarter earnings fell 11% on litigation expenses, impacts related to its Synthes Inc. acquisition and other items, though the acquisi...

  2. J&J Trims Executives' 2012 Bonuses by 10%

    Johnson & Johnson's (JNJ) "mixed" performance in 2012 prompted its board to reduce the planned bonus for Chief Executive Alex Gorsky and other senior officers by 10%...

  3. J&J Trims Executives' 2012 Bonuses by 10%, Citing Mixed Results

    Johnson & Johnson's (JNJ) "mixed" performance in 2012 prompted its board to reduce the planned bonus for Chief Executive Alex Gorsky and other senior officers by 10%...

  4. J&J 4th-Quarter Profit Soars On Fewer Charges, Synthes Buy

    Johnson & Johnson (JNJ) reported a surge in fourth-quarter earnings from a year-earlier period that was weighed down by legal costs, while an acquisition helped sale...

  5. Johnson & Johnson Profit Soars

    Johnson & Johnson's (JNJ) fourth-quarter earnings soared from a year-earlier period that included $2.9 billion in charges for hip product recalls, litigation losses ...

  6. J&J's 4Q Beats, Outlook Disappoints

    Johnson & Johnson (NYSE:JNJ) recorded higher fourth-quarter sales that were fueled by its acquisition of Synthes last year, just beating Wall Street's earnings proje...

  7. WEEK AHEAD: Fourth-Quarter Earnings Season Ramps Up

    Fourth-quarter earnings kick off in earnest next week, with reports due from technology majors Apple Inc. (AAPL), Google Inc. (GOOG) and International Business Machi...

  8. J&J CEO Gorsky to Be Chairman, as Weldon Will Retire in 2013

    Johnson & Johnson (JNJ) named its new chief executive, Alex Gorsky, as its new chairman, completing a leadership transition for the health-care conglomerate as its f...

  9. J&J profit beats as newer drugs, devices deliver

    Healthcare giant Johnson & Johnson reported better-than-expected third-quarter results on Tuesday, as newer drugs, including a treatment for prostate cancer, led a r...

  10. J&J 3rd-Quarter Profit Fell 7.3% Amid Acquisition-Related Costs

    Johnson & Johnson's (JNJ) third-quarter profit fell 7.3% on acquisition and research costs, while the recent purchase of medical-device maker Synthes fueled a 6.5% r...

  11. J&J third-quarter profit beats as drugs, devices deliver

    Johnson & Johnson reported better-than-expected quarterly results on Tuesday, as prescription drug sales rebounded with the help of newer products and jitters about ...

  12. Johnson & Johnson Profit Dips, Sales Increase

    Johnson & Johnson said Tuesday its third-quarter profit fell to $3 billion, or $1.05 a share, from $3.2 billion, or $1.15 a share, in the year-ago period. Adjusted p...

  1. Johnson & Johnson to Submit 10 New Product Filings by 2017

    Johnson & Johnson (JNJ) unit Janssen Pharmaceutical Co. said it plans to submit more than 10 new product filings and more than 25 significant brand line extensions b...

  2. J&J tops estimates as prescription, OTC drugs shine

    Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicine...

  3. J&J Sales Rise, Helped By Return of Recalled Products

    Johnson & Johnson (JNJ) reported an 8.5% increase in first-quarter revenue, helped by a medical-device acquisition, higher drug sales and the return to market of som...

  4. J&J tops estimates on strong prescription drug sales

    Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicine...

  5. J&J 1st-Quarter Profit Off 11% on Litigation Costs

    Johnson & Johnson (JNJ) reported a 10.6% decline in first-quarter profit as a result of litigation and other expenses, while a medical-device acquisition and higher ...

  6. Strong Drug Sales Lift J&J Above Street in 1Q

    Johnson & Johnson (NYSE:JNJ) reported surprising first-quarter earnings on Tuesday as demand for its global specialty and over-the-counter drugs increased and sales ...

  7. J&J Profit Off 11% on Litigation, Acquisitions

    Johnson & Johnson's (JNJ) first-quarter earnings fell 11% on litigation expenses, impacts related to its Synthes Inc. acquisition and other items, though the acquisi...

‹ Prev123Next ›
Freebase CC-BY
Source: Synthes Holding AG on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL